We are pleased to see our innovative approach to multi-payload ADCs featured in a recent article in Bioprocess Online! Our CSO, Philipp Spycher, discusses how our next generation ADC technology has the potential to address the key challenges in oncology: cancer heterogeneity and resistance. Check out the full article to learn about our novel technology and our plans to advance into the clinic: Araris Doubles Down With Dual-payload ADC (bioprocessonline.com) #Araris #ADC #AntibodyDrugConjugates #ADCTechnology #Clinic
Araris Biotech AG’s Post
More Relevant Posts
-
Bispecific ADCs have the potential to deliver enhanced efficacy over canonical ADC approaches for the same payload dose, and this is exactly what we see with ALM-401. Great to see this novel engineered Bispecific ADC progressing forward.
Almac Discovery announces the nomination of ALM-401 as a First in Class Bispecific Next Generation ADC for the treatment of refractory lung cancer to progress into pre-clinical development. Read more in our latest press release: https://hubs.li/Q02yXZyZ0
-
-
In case you missed it: Last week, the Immatics team was onsite in Houston, Texas, for the 39th Annual Society for Immunotherapy of Cancer (SITC) conference, where two oral presentations and multiple posters on our clinical and preclinical-stage candidates were presented. The conference was also a great opportunity for our Tübingen and Munich colleagues to connect with the Houston team. Thank you, SITC, for another outstanding and informative conference! Interested in the data? Read the full press release here: https://lnkd.in/dHUurcEv #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews #SITC
-
-
Obe-cel CAR T Therapy Achieves High Response Rates in R/R B-cell ALL: FELIX Trial Results Autolus Therapeutics MD Anderson Cancer Center FDA https://lnkd.in/e7riXFPt #ASH2024 #AutolusTherapeutics #BALL #Cancer #FDA #FELIXTrial #ObeCel #Obecabtagene #Autoleucel #OncoDaily #Oncology #R/R-Cell #B-ALL #Medcine #Health
-
-
Through Onco-PDO®, you will gain an additional insight into your tumor’s response against a panel of approved drugs. Hence, the data from your Onco-PDO® test report will allow your doctor to design a more personalized cancer treatment that will increase the positive outcomes. #PrecisionOncology #Livingsciences #CancerTreatment
-
-
Celebrating CARBOGEN AMCIS colleague Luca Mannocci! It's great to see our scientists' talents highlighted in industry trade publications! Learn more about our ADC and bioconjugation expertise by starting the conversation today! How can we help bring your science to life? #ADCs #bioconjugation #CDMO #bringingyoursciencetolife
📑 Exciting to see the latest ADC Contract Manufacturing Market Report by PharmaSource highlighting the growth potential of Antibody-Drug Conjugates (ADCs). Proud to see CARBOGEN AMCIS featured as an important player in this dynamic sector, with valuable insights from one of our own scientists Luca Mannocci. ADCs are truly shaping the future of cancer therapy! 🔗 Check out the report for more details: https://lnkd.in/gY4cEK8y #ADC #CDMO #PharmaInnovation #CancerTherapy PharmaSource
-
-
ESMO 2024 Quick Takes with LARVOL: Guru Sonpavde, MD In this post-ESMO 2024 Quick Take, Dr. Guru Sonpavde, MD, shares his insights on the practice-changing NIAGARA trial. This randomized phase 3 study, involving approximately 1,000 patients, evaluated neoadjuvant gemcitabine, cisplatin, with or without durvalumab for muscle-invasive bladder cancer. The results showed significant improvements in both event-free survival (hazard ratio: 0.68) and overall survival (hazard ratio: 0.75), signaling a major shift in treatment approaches. Stay tuned for more post-ESMO reflections and updates on how this trial may shape future clinical practice. #ESMO24 #CancerResearch #NIAGARATrial #LARVOLQuickTake
-
#ai and machine learning is revolutionizing the development of #mAbs. These cutting-edge technologies can lead to more efficient and targeted therapeutic solutions. Check out what Aulos Bioscience is doing in #oncology.
What if #AI could design a drug that helps solve one of the biggest challenges in immunotherapy? At Aulos, we believe our lead asset, AU-007, could be the answer in safely harnessing the power of IL-2 to fight solid tumor cancers effectively. Learn how Aulos' approach works: https://bit.ly/4cao1MO #Biopharma #Innovation #Oncology
-
Curasight and Curium sign global radioisotope supply agreement for uTREAT® - Agreement ensures supply of non-carrier-added Lutetium-177 for uTREAT® development and commercial supply including plans for upcoming pivotal therapy trials - The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer. #curasight #curium #cancer #partnership #theranostic #utreat #utrace
-
Business Development Manager @ Parexel | Sales Target Management | French, Spanish, English speaker
In our New Medicines, Novel Insights Oncology report, Dr. Gwyn Bebb reflects on the paradoxes and challenges we encounter while striving to make precision oncology a reality and his vision for the future. Hear from Dr. Bebb on the complexities of treating each patient with the exact right medicine ─ and why we must realize the vision: https://lnkd.in/eYb8q_Vu #ParexelBiotech #CancerResearch #Oncology #NovelInsights
-
𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 (𝗧𝗥𝗧𝘀) are changing the game in cancer treatment by delivering cytotoxic radiation directly to tumors with unparalleled precision. Our latest blog by Diane-Charlotte Imbs, Kenny Watson, and Amandine Manon explores the technology behind TRTs. Our experts explain 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗙𝗗𝗔 𝗮𝗻𝗱 𝗘𝗠𝗔 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 𝗮𝗻𝗱 𝗱𝗶𝘀𝗰𝘂𝘀𝘀 𝘄𝗵𝗮𝘁 𝘁𝗵𝗲𝘆 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗱𝗿𝘂𝗴𝘀. Click here to learn about the potential of TRTs: https://ow.ly/5C4p50QZ5OB #CancerResearch #TargetedRadiationTherapy #CancerTreatment #Oncology #ClinicalTrials #FDAguidelines #EMAguidelines #ProjectOptimus #ModelingSimulation #PKdata #DoseSelection #ClinicalPharmacology
-
